Moleculin Biotech (MBRX)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
alles kan beter
Berichten: 649
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 235

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 13 Jul 2018 06:15

neku schreef:
neku schreef:+5% erbij vandaag :clap:

gezakt naar +1,78 :think:

tja, dit lijkt een keryx aandeeltje.... :think:
Just when you think you've hit rock bottom, someone will hand you a shovel.

Forum actieveling
Forum actieveling
Berichten: 950
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 397

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 18 Jul 2018 15:05

HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun preclinical toxicology testing of its WP1732, a fully water-soluble STAT3 inhibitor through its new subsidiary in Australia.

“Based on preclinical testing, we believe the discovery of WP1732, a fully water-soluble STAT3 inhibitor, has the potential to be a breakthrough discovery for rare and difficult to treat cancers. As a result of our preclinical testing, we have recieved multiple requests to commence clinical trials and we are pleased to be taking the next steps in preparing for the appropriate clinical work,” commented Walter Klemp, Chairman and CEO of Moleculin. “By utilizing our subsidiary in Australia and the attractive R&D tax credits it offers, we can accelerate the preclinical work of WP1732 and maintain a strong cash balance. We believe this will allow us to complete our IND-enabling work and meet FDA submission requirements before year-end while also reducing our total cost of development.”
alles kan beter liked last!